We met with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the new drugs and developing treatment regimens for drug-resistant tuberculosis.
The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Questions:
- What are the most important second wave drugs for the treatment of tuberculosis, and what advantages do they offer over older drugs? (0:25)
- Could you tell us a little about the NixTB clinical trial, its findings and their impact on clinical practice? (2:48)
- What biomarkers seem useful in the development of drugs and regimens? (5:39)
Disclosures:
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
